Pivotal Week Ahead for PDS Biotechnology Shares
Published on 11/03/2025 at 13:02 | Redaktion boerse-global.de
PDS Biotechnology Corp (PDSB) is approaching a week of significant developments, with two major catalysts on the horizon. The clinical-stage company is pursuing an accelerated regulatory pathway for its lead cancer immunotherapy candidate, PDS0101, while also anticipating the release of fresh clinical data.
In a strategic move to fast-track its oncology treatment, PDS Biotech has formally requested a meeting with the U.S. Food and Drug Administration. The company aims to discuss a potential accelerated approval pathway for PDS0101, which targets HPV16-positive head and neck cancers. Central to this initiative is a proposed amendment to the protocol of its ongoing VERSATILE-003 Phase 3 clinical trial. PDS Biotech seeks to establish Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
